Clinicoradiological characteristics of primary spinal cord H3 K27M-mutant diffuse midline glioma

View More View Less
  • 1 Department of Neurosurgery, Xuanwu Hospital, China International Neuroscience Institute, Capital Medical University, Beijing; and
  • | 2 Department of Pathology, Xuanwu Hospital, Capital Medical University, Beijing, China
Restricted access

Purchase Now

USD  $45.00

Spine - 1 year subscription bundle (Individuals Only)

USD  $376.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
Print or Print + Online

OBJECTIVE

Primary spinal cord H3 K27M-mutant diffuse midline glioma (DMG) is a rare and devastating pathological entity. However, little attention has been paid to this disease. As a result, its clinicoradiological characteristics have yet to be described. The aim of this study was to describe the clinicoradiological characteristics of primary intramedullary H3 K27M-mutant DMG and to compare this tumor with the H3 K27 wild-type to explore potential features that could differentiate the two.

METHODS

A total of 59 patients with pathologically confirmed intramedullary astrocytoma were included in this study. The cohort was divided into an H3 K27M-mutant group and H3 K27 wild-type group based on the status of H3 K27M according to an immunohistochemistry method. Demographic data, MRI features, and molecular information were collected. Multivariate logistic regression was conducted to investigate variables that might have a role in differentiating an H3 K27M DMG from an H3 K27 wild-type tumor.

RESULTS

Only symptom duration showed an independent association with the H3 K27M mutation (OR 0.82, 95% CI 0.68–0.94, p = 0.016). Patients with spinal cord H3 K27M-mutant DMG had a shorter symptom duration than patients with H3 K27 wild-type glioma. No significant difference was found in terms of MRI features between the H3 K27M-mutant and H3 K27 wild-type groups. Additionally, H3 K27M-mutant DMG frequently demonstrated overexpression of p53. Survival outcome did not show a statistical difference between the H3 K27-mutant subgroup and H3 K27 wild-type subgroup in histologically high-grade astrocytoma.

CONCLUSIONS

Symptom duration was associated with an H3 K27M mutation in intramedullary astrocytoma. MRI features were heterogeneous, and no imaging feature was able to predict the H3 K27M mutation. The H3 K27M mutation did not impact survival outcome in spinal histologically high-grade astrocytoma.

ABBREVIATIONS

CNS = central nervous system; DMG = diffuse midline glioma; EOR = extent of resection; GBM = glioblastoma; GTR = gross-total resection; MMS = modified McCormick scale; PR = partial resection; TMZ = temozolomide; WHO = World Health Organization.

Supplementary Materials

    • Supplementary Figure 1 (PDF 1,183 KB)

Spine - 1 year subscription bundle (Individuals Only)

USD  $376.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
  • 1

    Guidetti B, Mercuri S, Vagnozzi R. Long-term results of the surgical treatment of 129 intramedullary spinal gliomas. J Neurosurg. 1981;54(3):323330.

    • Search Google Scholar
    • Export Citation
  • 2

    Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol. 2019;21(suppl 5):v1v100.

    • Search Google Scholar
    • Export Citation
  • 3

    Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803820.

    • Search Google Scholar
    • Export Citation
  • 4

    Manzano G, Green BA, Vanni S, Levi AD. Contemporary management of adult intramedullary spinal tumors—pathology and neurological outcomes related to surgical resection. Spinal Cord. 2008;46(8):540546.

    • Search Google Scholar
    • Export Citation
  • 5

    Henker C, Kriesen T, Schneider B, et al. Correlation of Ki-67 index with volumetric segmentation and its value as a prognostic marker in glioblastoma. World Neurosurg. 2019;125:e1093e1103.

    • Search Google Scholar
    • Export Citation
  • 6

    Tuite GF, Thompson DNP, Austin PF, Bauer SB. Evaluation and management of tethered cord syndrome in occult spinal dysraphism: recommendations from the international children’s continence society. Neurourol Urodyn. 2018;37(3):890903.

    • Search Google Scholar
    • Export Citation
  • 7

    Aboian MS, Solomon DA, Felton E, et al. Imaging characteristics of pediatric diffuse midline gliomas with histone H3 K27M mutation. AJNR Am J Neuroradiol. 2017;38(4):795800.

    • Search Google Scholar
    • Export Citation
  • 8

    Qiu T, Chanchotisatien A, Qin Z, et al. Imaging characteristics of adult H3 K27M-mutant gliomas. J Neurosurg. 2020;133(6):16621670.

  • 9

    Chiang J, Diaz AK, Makepeace L, et al. Clinical, imaging, and molecular analysis of pediatric pontine tumors lacking characteristic imaging features of DIPG. Acta Neuropathol Commun. 2020;8(1):57.

    • Search Google Scholar
    • Export Citation
  • 10

    Zhang YW, Chai RC, Cao R, et al. Clinicopathological characteristics and survival of spinal cord astrocytomas. Cancer Med. 2020;9(19):69967006.

    • Search Google Scholar
    • Export Citation
  • 11

    Lebrun L, Meléndez B, Blanchard O, et al. Clinical, radiological and molecular characterization of intramedullary astrocytomas. Acta Neuropathol Commun. 2020;8(1):128.

    • Search Google Scholar
    • Export Citation
  • 12

    Gessi M, Gielen GH, Dreschmann V, et al. High frequency of H3F3A (K27M) mutations characterizes pediatric and adult high-grade gliomas of the spinal cord. Acta Neuropathol. 2015;130(3):435437.

    • Search Google Scholar
    • Export Citation
  • 13

    Zou Y, Sun J, Zhou Y, et al. Prognostic factors and treatment of spinal astrocytomas: a multi-institutional cohort analysis. Spine (Phila Pa 1976).2018;43(10):E565E573.

    • Search Google Scholar
    • Export Citation
  • 14

    Abd-El-Barr MM, Huang KT, Chi JH. Infiltrating spinal cord astrocytomas: epidemiology, diagnosis, treatments and future directions. J Clin Neurosci. 2016;29:1520.

    • Search Google Scholar
    • Export Citation
  • 15

    Chai RC, Zhang YW, Liu YQ, et al. The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation. Acta Neuropathol Commun. 2020;8(1):40.

    • Search Google Scholar
    • Export Citation
  • 16

    Wang L, Li Z, Zhang M, et al. H3 K27M-mutant diffuse midline gliomas in different anatomical locations. Hum Pathol. 2018;78:8996.

  • 17

    Yi S, Choi S, Shin DA, et al. Impact of H3.3 K27M mutation on prognosis and survival of grade IV spinal cord glioma on the basis of new 2016 World Health Organization classification of the central nervous system. Neurosurgery. 2019;84(5):10721081.

    • Search Google Scholar
    • Export Citation
  • 18

    Huang TY, Piunti A, Lulla RR, et al. Detection of histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Acta Neuropathol Commun. 2017;5(1):28.

    • Search Google Scholar
    • Export Citation
  • 19

    Stallard S, Savelieff MG, Wierzbicki K, et al. CSF H3F3A K27M circulating tumor DNA copy number quantifies tumor growth and in vitro treatment response. Acta Neuropathol Commun. 2018;6(1):80.

    • Search Google Scholar
    • Export Citation
  • 20

    Kim DH, Kim JH, Choi SH, et al. Differentiation between intramedullary spinal ependymoma and astrocytoma: comparative MRI analysis. Clin Radiol. 2014;69(1):2935.

    • Search Google Scholar
    • Export Citation
  • 21

    Solomon DA, Wood MD, Tihan T, et al. Diffuse midline gliomas with histone H3-K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol. 2016;26(5):569580.

    • Search Google Scholar
    • Export Citation
  • 22

    Aboian MS, Tong E, Solomon DA, et al. Diffusion characteristics of pediatric diffuse midline gliomas with histone H3-K27M mutation using apparent diffusion coefficient histogram analysis. AJNR Am J Neuroradiol. 2019;40(11):18041810.

    • Search Google Scholar
    • Export Citation
  • 23

    Takai K, Tanaka S, Sota T, et al. Spinal cord astrocytoma with isocitrate dehydrogenase 1 gene mutation. World Neurosurg. 2017;108:991.e13991.e16.

    • Search Google Scholar
    • Export Citation
  • 24

    Konovalov NA, Asyutin DS, Shayhaev EG, et al. Rare cases of IDH1 mutations in spinal cord astrocytomas. Acta Naturae. 2020;12(2):7073.

  • 25

    Takami H, Yoshida A, Fukushima S, et al. Revisiting TP53 mutations and immunohistochemistry—a comparative study in 157 diffuse gliomas. Brain Pathol. 2015;25(3):256265.

    • Search Google Scholar
    • Export Citation
  • 26

    Takano S, Ishikawa E, Sakamoto N, et al. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas. Brain Tumor Pathol. 2016;33(2):107116.

    • Search Google Scholar
    • Export Citation
  • 27

    Gillet E, Alentorn A, Doukouré B, et al. TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas. J Neurooncol. 2014;118(1):131139.

    • Search Google Scholar
    • Export Citation
  • 28

    Wong LH, McGhie JD, Sim M, et al. ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. Genome Res. 2010;20(3):351360.

    • Search Google Scholar
    • Export Citation
  • 29

    Ikemura M, Shibahara J, Mukasa A, et al. Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas. Histopathology. 2016;69(2):260267.

    • Search Google Scholar
    • Export Citation
  • 30

    Ludwig K, Kornblum HI. Molecular markers in glioma. J Neurooncol. 2017;134(3):505512.

  • 31

    Shankar GM, Lelic N, Gill CM, et al. BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology. Acta Neuropathol. 2016;131(1):147150.

    • Search Google Scholar
    • Export Citation
  • 32

    Zhang M, Iyer RR, Azad TD, et al. Genomic landscape of intramedullary spinal cord gliomas. Sci Rep. 2019;9(1):18722.

  • 33

    Liu DK, Wang J, Guo Y, et al. Identification of differentially expressed genes and fusion genes associated with malignant progression of spinal cord gliomas by transcriptome analysis. Sci Rep. 2019;9(1):13583.

    • Search Google Scholar
    • Export Citation
  • 34

    Sloan EA, Cooney T, Oberheim Bush NA, et al. Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas. Acta Neuropathol. 2019;138(5):877881.

    • Search Google Scholar
    • Export Citation
  • 35

    Alvi MA, Ida CM, Paolini MA, et al. Spinal cord high-grade infiltrating gliomas in adults: clinico-pathological and molecular evaluation. Mod Pathol. 2019;32(9):12361243.

    • Search Google Scholar
    • Export Citation
  • 36

    Zadnik PL, Gokaslan ZL, Burger PC, Bettegowda C. Spinal cord tumours: advances in genetics and their implications for treatment. Nat Rev Neurol. 2013;9(5):257266.

    • Search Google Scholar
    • Export Citation
  • 37

    Cheng L, Yao Q, Ma L, et al. Predictors of mortality in patients with primary spinal cord glioblastoma. Eur Spine J. 2020;29(12):32033213.

  • 38

    Hernández-Durán S, Bregy A, Shah AH, et al. Primary spinal cord glioblastoma multiforme treated with temozolomide. J Clin Neurosci. 2015;22(12):18771882.

    • Search Google Scholar
    • Export Citation
  • 39

    Kim WH, Yoon SH, Kim CY, et al. Temozolomide for malignant primary spinal cord glioma: an experience of six cases and a literature review. J Neurooncol. 2011;101(2):247254.

    • Search Google Scholar
    • Export Citation
  • 40

    Banan R, Christians A, Bartels S, et al. Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant. Acta Neuropathol Commun. 2017;5(1):98.

    • Search Google Scholar
    • Export Citation
  • 41

    Shen G, Ma H, Pan L, et al. FDG PET/CT and MRI in primary spinal cord glioblastoma. Clin Nucl Med. 2020;45(3):e144e145.

  • 42

    Kebir S, Kimmich O, Niehusmann P, et al. 18F-fluoroethyl-L-tyrosine positron emission tomography-guided diagnosis of a malignant intramedullary spinal cord tumor. Oncol Lett. 2016;12(6):47054707.

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 54 54 54
Full Text Views 43 43 43
PDF Downloads 46 46 46
EPUB Downloads 0 0 0